Home > > > > > Report Detail

Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022

Publisher Name :
Date: 25-Jan-2018
No. of pages: 172

Executive Summary

The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Migraine Pipeline Drugs Market by assessing the potential of the seven drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the seven drugs, the product profile, description and regulatory phase of each of the seven drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the seven drugs to present the current perspective.

The report titled “Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022” also analyzes the overall sizing, growth and forecast of Migraine Drugs Market By Type (Acute and Prophylaxis) for the global market as well as for countries including United States, United Kingdom, Japan, France, Italy and Germany.

Over the recent years, the Migraine Drugs market is growing rapidly due to rising prevalence of migraine patients around the world. Globally, the growth of Migraine Drugs market is driven by rising awareness regarding migraine and available treatments

The global migraine drugs market is projected to display a robust growth represented by a CAGR of 14.48% during 2017– 2022, chiefly driven by rising consumption of unhealthy food coupled with unmet need By the present drugs for the treatment of migraine.  The report has covered and analysed the present migraine drugs in the market and has also analysed potential of seven major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global migraine pipeline drugs market.

Scope of the Report

Migraine Pipeline Drugs Assessment Drug X1, X2, X3, X4, X5, X6, X7 (Forecast Period: 2019-2022)


  • Market Potential

  • Clinical Trials

  • Product Description

  • Regulatory Phases

  • 7Ps Analysis


Global Migraine Drugs Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)


  • Market Sizing and Growth

  • Market Sizing and Growth By Type Acute and Prophylaxis


Country Analysis US, UK, Japan, France, Italy, Germany (Actual Period: 2012-2016, Forecast Period: 2017-2022)


  • Market Sizing and Growth


Other Report Highlights


  • Market Dynamics Drivers, Challenges

  • Company Analysis Amgen Biopharmaceuticals, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline  


Customization of the Report

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research. 

Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022

Table of Contents

1. Research Methodology

2. Executive Summary

3. Migraine - An Overview
3.1. Symptoms of migraine
3.2. Stages of Migraine
3.3.Types of Migraine
3.4. Types of migraine on the basis of frequency of occurrence

4. Treatment of Migraine
4.1. Goal of Migraine Treatment
4.2. Treatment of Migraine - Pharmacological and Non-Pharmacological
4.2.1. Pharmacological treatment of migraine
4.2.2. Pharmacological - Abortive
4.2.3. Pharmacological - Preventive
4.2.4. Non-Pharmacological Treatment of Migraine
4.2.5. Non- Pharmacological - Surgical
4.2.6. Non- Pharmacological - Non-Surgical

5. Anti-Migraine Pipeline Drugs Analysis
5.1. Anti-Migraine Pipeline Drugs (According to Mechanism of Working)
5.2. Anti-Migraine Pipeline Drugs (Ergotamine): Drug - X1
5.2.1. Description
5.2.2. Regulatory Milestones
5.2.3. Advantages & Disadvantages
5.2.4. Product Profile & Expected Launch
5.2.5. Clinical Trials and Status
5.2.6. Pivotal Clinical Trials and Results
5.2.7. Drug X-1- Global Market Potential
5.2.8. Drug X-1- 7Ps Analysis
5.3. Anti-Migraine Pipeline Drugs (Anti-5HT Receptor Agonist): Drug - X2
5.3.1. Description
5.3.2. Regulatory Milestones
5.3.3. Advantages & Disadvantages
5.3.4. Product Profile & Expected Launch
5.3.5. Clinical Trials and Status
5.3.6. Pivotal Clinical Trials and Results
5.3.7. Drug - X2 - Global Market Potential
5.3.8. Drug - X2 - 7Ps Analysis
5.4. Anti-Migraine Pipeline Drugs (Anti CGRPs)
5.5. Anti-Migraine Pipeline Drugs (Anti CGRPs) - By Drug
5.6. Anti-Migraine Pipeline Drugs (CGRP Antagonist): Drug - X3
5.6.1. Description
5.6.2. Regulatory Milestones
5.6.3. Advantages & Disadvantages
5.6.4. Product Profile & Expected Launch
5.6.5. Clinical Trials and Status
5.6.6. Pivotal Clinical Trials and Results
5.6.7. Drug - X3 - Global Market Potential
5.6.8. Drug - X3 - 7Ps Analysis
5.7. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X4
5.7.1. Description
5.7.2. Regulatory Milestones
5.7.3. Advantages & Disadvantages
5.7.4. Product Profile & Expected Launch
5.7.5. Clinical Trials and Status
5.7.6. Pivotal Clinical Trials and Results
5.7.7. Drug - X4 - Global Market Potential
5.7.8. Drug - X4 - 7Ps Analysis
5.8. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X5
5.8.1. Description
5.8.2. Regulatory Milestones
5.8.3. Advantages & Disadvantages
5.8.4. Product Profile & Expected Launch
5.8.5. Clinical Trials and Status
5.8.6. Pivotal Clinical Trials and Results
5.8.7. Drug - X5 - Global Market Potential
5.8.8. Drug - X5 - 7Ps Analysis
5.9. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X6
5.9.1. Description
5.9.2. Regulatory Milestones
5.9.3. Advantages & Disadvantages
5.9.4. Product Profile & Expected Launch
5.9.5. Clinical Trials and Status
5.9.6. Pivotal Clinical Trials and Results
5.9.7. Drug - X6 - Global Market Potential
5.9.8. Drug - X6 - 7Ps Analysis
5.10. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X7
5.10.1. Description
5.10.2. Regulatory Milestones
5.10.3. Advantages & Disadvantages
5.10.4. Product Profile & Expected Launch
5.10.5. Clinical Trials and Status
5.10.6. Pivotal Clinical Trials and Results
5.10.7. Drug - X7 - Global Market Potential
5.10.8. Drug - X7 - 7Ps Analysis

6. Global Migraine Drugs Market: Growth and Forecast
6.1. By Value (2012-2016)
6.2. By Value (2017-2022)

7. Global Migraine Drugs Market - Analysis By Type
7.1. Global Migraine Drugs Market, By Type: Breakdown (%)
7.1.1. Global Migraine Drugs Market- By Type: 2016 (%)
7.1.2. Global Migraine Drugs Market By Type: 2022 (%)
7.2. Global Migraine Drugs Market- By Acute
7.2.1. By Value (2012-2016)
7.2.2. By Value (2017-2022)
7.3. Global Migraine Drugs Market- By Prophylaxis
7.3.1. By Value (2012-2016)
7.3.2. By Value (2017-2022)

8. Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany,  ROW)                                                                                         
8.1. U.S. Migraine Drugs Market, By Value (2012-2022)
8.2. U.K. Migraine Drugs Market, By Value (2012-2022)
8.3. Japan Migraine Drugs Market, By Value (2012-2022)
8.4. France Migraine Drugs Market, By Value (2012-2022)
8.5. Italy Migraine Drugs Market, By Value (2012-2022)
8.6. Germany Migraine Drugs Market, By Value (2012-2022)
8.7. ROW Migraine Drugs Market, By Value (2012-2022)

9. Market Dynamics
9.1. Migraine Drug Market Drivers
9.2. Migraine Drug Market Challenges

10. Company Profiles
10.1. Amgen
10.2. Allergan
10.3. Eli Lilly
10.4. Alder Pharmaceuticals
10.5. Teva Pharmaceuticals
10.6. Vernalis
10.7. Pfizer
10.8. Impax Laboratories
10.9. Glaxo Smithkline

List of Tables

Table A: Summary of Completed Clinical Trials of Drug - X1
Table B: Summary of Completed & ongoing Clinical Trials of Drug - X1
Table C: Summary of Completed & ongoing Clinical Trials of Drug - X1
Table D: Number and percentage of patients who reported each particular TEAE with safety population for each dose.
Table E: Summary of Completed & ongoing Clinical Trials of Drug - X2
Table F: Summary of Completed & ongoing Clinical Trials of Drug - X3
Table G: Summary of Completed Clinical Trials of Drug - X4
Table H: Summary of Ongoing Clinical Trials of Drug - X5
Table I: Summary of Completed & Ongoing Clinical Trials of Drug - X6
Table J: Summary of Completed & Ongoing Clinical Trials of Drug - X7

List of Figures

Figure 1: 2 hour pain relief & pain free rates in patients treated with LEVADEX (MAP0004) compared to placebo (1st pivotal trial)
Figure 2: Improvement at two hours in people who took LEVADEX compared to Placebo (2nd pivotal trial)
Figure 3: Global Drug - X1 Market Size, By Value, Forecast, 2019-2022 (USD Billion)
Figure 4: Percentage of patients achieving primary end point
Figure 5: Percentage of patients achieving secondary endpoint
Figure 6: Global Drug - X2 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 7: Efficacy in 2 hour pain freedom
Figure 8: Global Drug - X3 Market Size, By Value, Forecast, 2019-2022 (USD Billion)
Figure 9: Reduction in Monthly migraine days - weeks 1 through 12
Figure 10: Percentage of patients with =75% reduction in number of migraine days - weeks 1 through 24
Figure 11: Percentage of patients with 100% response rate (no migraine in any given month) - months 1 through 6
Figure 12: Global Drug - X4 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 13: Global Drug - X5 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 14: Global Drug - X6 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 15: Monthly migraine days reduction vs placebo in previous prophylactic drugs failure group
Figure 16: Reduction in days using acute pain medications in recent drug overuse group
Figure 17: Global Drug - X7 Market Size, By Value, Forecast, 2019-2022 (USD Million)
Figure 18: Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion)
Figure 19: Global Migraine Drugs Market Size, By Value, Forecast, 2017-2022 (USD Billion)
Figure 20: Global consumption of chocolate confectionary, By volume (in 1000 metric tones)
Figure 21: Global Migraine Drugs Market Share, By Type, 2016 (%)
Figure 22: Global Migraine Drugs Market Share, By Type, 2022 (%)
Figure 23: Global Migraine Drugs Market, By Acute, By Value, 2012-2016 (USD Million)
Figure 24: Global Migraine Drugs Market, By Acute, By Value, 2017-2022 (USD Million)
Figure 25: Global Migraine Drugs Market, By Prophylaxis, By Value, 2012-2016 (USD Million)
Figure 26: Global Migraine Drugs Market, By Prophylaxis, By Value, 2017-2022 (USD Million)
Figure 27: U.S. Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 28: U.S. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 29: U.S Adult Migraine Patients, In Percentage
Figure 30: U.S Migraine Patients, By gender, In Percentage
Figure 31: U.K Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 32: U.K. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 33: U.K. Migraine Patient, In Percentage
Figure 34: NHS Budget for mental illness, In Billion  
Figure 35: Japan Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 36: Japan Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 37: Japan Migraine Patient out of total population, In Percentages
Figure 38: France Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 39: France Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 40: France Migraine Patient, In Percentage
Figure 41: Unemployment rate in France in percentage  
Figure 42: Italy Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 43: Italy Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 44: Italy Migraine Patient out of total population, In Percentages
Figure 45: Italy Unemployment rate, In Percentages
Figure 46: Germany Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 47: Germany Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 48: Germany Migraine Patient out of total population, In Percentages
Figure 49: First Time asylum application, In Number
Figure 50: ROW Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Figure 51: ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Figure 52: Total global sales of Allergan's Botox in 2016 and forecasted for 2022 (USD Million)

  • Global Narcolepsy Drug Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 80
    According to our LPI (LP Information) latest study, the global Narcolepsy Drug market size was valued at US$ 2715.1 million in 2023. With growing demand in downstream market, the Narcolepsy Drug is forecast to a readjusted size of US$ 5598.9 million by 2030 with a CAGR of 10.9% during review period. The research report highlights the growth potential of the global Narcolepsy Drug market. Narcolepsy Drug are expected to show stable growth in the future market. However, product differentia......
  • Global Epilepsy Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 121
    Market Overview of Global Epilepsy Drugs market: According to our latest research, the global Epilepsy Drugs market looks promising in the next 5 years. As of 2022, the global Epilepsy Drugs market was estimated at USD 4815.92 million, and it's anticipated to reach USD 6053.85 million in 2028, with a CAGR of 3.89% during the forecast years. Anti-epileptic drugs can eliminate or reduce seizures in two ways. One is to affect central neurons to prevent or reduce their pathologic......
  • Global Neuromyelitis Optica Drug Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 107
    According to our LPI (LP Information) latest study, the global Neuromyelitis Optica Drug market size was valued at US$ 46 million in 2023. With growing demand in downstream market, the Neuromyelitis Optica Drug is forecast to a readjusted size of US$ 57 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Neuromyelitis Optica Drug market. Neuromyelitis Optica Drug are expected to show stable growth in the future marke......
  • Migraine Drugs - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 118
    The global Migraine Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Migraine Drugs in various end use industries. The expanding demands from the Hospitals, Clinics, Household Use and Others, are propelling Migraine Drugs market. Sumatriptan, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in......
  • Global Neuromyelitis Optica Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 19-Dec-2023        Price: US 3380 Onwards        Pages: 121
    Market Overview of Global Neuromyelitis Optica Drug market: According to our latest research, the global Neuromyelitis Optica Drug market looks promising in the next 5 years. As of 2022, the global Neuromyelitis Optica Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the glo......
  • Global Narcolepsy Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 126
    Market Overview of Global Narcolepsy Drug market: According to our latest research, the global Narcolepsy Drug market looks promising in the next 5 years. As of 2022, the global Narcolepsy Drug market was estimated at USD 2915.59 million, and it's anticipated to reach USD 5983.81 million in 2028, with a CAGR of 12.73% during the forecast years. Narcolepsy is a neurological disorder characterized by the brain's inability to control sleep/wakefulness cycles. This......
  • Global Edaravone Market Research Report 2023
    Published: 05-Dec-2023        Price: US 2900 Onwards        Pages: 88
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Edaravone market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Mitsubishi Tanabe Pharma - Simcere - Taj Pharmaceuticals Ltd. - Sun Pharmaceutical Industries Ltd. - Unichem Laboratories Ltd - UCB India Ltd - Piram......
  • Global Ethoxyquin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Ethoxyquin market: According to our latest research, the global Ethoxyquin market looks promising in the next 5 years. As of 2022, the global Ethoxyquin market was estimated at USD 216.07 million, and it's anticipated to reach USD 303.42 million in 2028, with a CAGR of 5.82% during the forecast years. Ethoxyquin (EQ) is a clear, viscous, light yellow to dark brown liquid, with an unpleasant, mercaptan-like smell, that causes irritation of the skin an......
  • Global Antipsychotic Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Oct-2023        Price: US 3380 Onwards        Pages: 117
    Market Overview of Global Antipsychotic Drugs market: According to our latest research, the global Antipsychotic Drugs market looks promising in the next 5 years. As of 2022, the global Antipsychotic Drugs market was estimated at USD 15363.6 million, and it's anticipated to reach USD 23658.8 million in 2028, with a CAGR of 7.46% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global An......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs